A commentary notes that “to date, the pharmaceutical industry has not presented transparent explanations or calculations underlying their pricing decisions. In some countries experiments were started with managed entry agreements, such as pay-for-performance arrangements, but no methodologically sound reports have been presented that show a decrease in overall costs at a national level. Neither are we aware of agreements whereby the innovation is rewarded and prices reduce relative to sales volume.” It adds that the societal challenge is to combine the development and availability of promising new drugs with the sustainability of the healthcare system, therefore innovative and sustainable business models need to be agreed to ensure fast access to relevant drugs for patients with cancer.